Galina Marder, MD
Rheumatology · New Hyde Park, NYNPI 1851470058
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,798 of the $20,655 with a category attached, or 91.0%. 7 manufacturers reported payments, led by Boehringer Ingelheim at 54.7% of the total. 2025 is the largest year on record at $10,784, 4.3 times the $2,480 reported in 2020.
Across 23 payments — averaging $898.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$11K
- AstraZeneca$3K
- Janssen Scientific Affairs, LLC$2K
- Amgen$2K
- Genentech, Inc.$1K
- Argenx US, Inc.$900
- plus $317 from 1 others
Across 105 payments — averaging $9365.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$536K
- Astrazeneca UK Limited$156K
- Argenx US, Inc.$89K
- AstraZeneca$84K
- CSL Behring$56K
- E.r. Squibb & Sons, L.L.C.$52K
- plus $11K from 1 others
What the payments were for
- Consulting fees$18,79891%
- Speaking & faculty fees$2001%
- Travel & lodging$1,1616%
- Food & beverage$4962%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $11,304 |
| AstraZeneca(2 entities) | 3 | $3,161 |
| Janssen Scientific Affairs, LLC | 3 | $2,192 |
| Amgen | 2 | $1,651 |
| Genentech, Inc. | 1 | $1,130 |
| Argenx US, Inc. | 1 | $900 |
| Vertex | 1 | $317 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,655 in reported general payments places this provider in the 80th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 34 | $679,526 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 30 | $420,755 |
| Actemra ActpenTocilizumab | 54 | $292,845 |
| BenlystaBelimumab | 20 | $141,786 |
| Xeljanz XrTofacitinib Citrate | 15 | $80,013 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $69,891 |
| OtrexupMethotrexate/Pf | 14 | $16,707 |
| Mycophenolic AcidMycophenolate Sodium | 23 | $15,505 |
| Atovaquone | 30 | $7,233 |
| Hydroxychloroquine Sulfate | 171 | $6,054 |
| Mycophenolate Mofetil | 47 | $5,313 |
| Lidocaine | 29 | $4,523 |
| Diclofenac Sodium | 32 | $4,030 |
| Duloxetine Hcl | 170 | $2,993 |
| Leflunomide | 41 | $2,775 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in New Hyde Park
- Richard FurieNew Hyde Park$746K
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Barry GruberBabylon$742K
- Olga PetrynaNew York$509K
- Sanjay GodhwaniWading River$472K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.